Document Detail


Kinase dysfunction and kinase inhibitors.
MedLine Citation:
PMID:  23331696     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
With recent advances in molecular biology, abnormalities in cancer cells that contribute to dysregulation of cell survival and proliferation are being characterized with greater precision. Through this process, key abnormalities in cancer cells involving proteins that regulate signal transduction, migration, mitosis and other critical processes have been identified. Such abnormalities often involve a class of proteins called kinases that act to phosphorylate other proteins in the cell, resulting in activation of these proteins in the absence of appropriate stimulation/regulation. Given their role in tumour biology, substantial effort has been directed at blocking the function of these proteins. Several approaches have been used, including monoclonal antibodies and small molecule inhibitors. While antibodies are primarily directed at cell surface proteins, small molecule inhibitors, also known as kinase inhibitors, target proteins throughout the cell. A variety of kinase inhibitors have been approved for the treatment of human cancers. In some instances, these inhibitors have exhibited significant clinical efficacy, and it is likely that their biological activity will be further enhanced as combination regimens with standard treatment modalities are explored. The use of kinase inhibitors in dogs and cats is relatively recent, although two inhibitors, toceranib (Palladia; Pfizer Animal Health, Madison, NJ, USA) and masitinib (Kinavet; Catalent Pharma Solutions, Somerset, NJ, USA) have been approved by the Federal Drug Administration (USA) for use in dogs. This article reviews the biology of protein kinase dysfunction in human and animal cancers, and the application of specific kinase inhibitors to veterinary cancer patients.
Authors:
Cheryl A London
Related Documents :
15247276 - Protein phosphatase 2a, a negative regulator of the erk signaling pathway, is activated...
23604126 - The role of dab2ip in androgen receptor activation during prostate cancer progression.
10876086 - Neuroprotection by mapk/erk kinase inhibition with u0126 against oxidative stress in a ...
11162246 - Phosphorylation of extracellular signal-regulated kinase after transient cerebral ische...
18502966 - Mechanical stress induces osteopontin via atp/p2y1 in periodontal cells.
18608006 - Actin filaments and microtubules regulate endocytosis in marginal cells of the stria va...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Veterinary dermatology     Volume:  24     ISSN:  1365-3164     ISO Abbreviation:  Vet. Dermatol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9426187     Medline TA:  Vet Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  181-e40     Citation Subset:  IM    
Copyright Information:
© 2013 The Author. Veterinary Dermatology © 2013 ESVD and ACVD.
Affiliation:
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43214, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Advances in the management of skin cancer.
Next Document:  The contribution of stem cells to epidermal and hair follicle tumours in the dog.